Inverness Medical Switzerland GmbH v. Acon Laboratories, Inc.

367 F. Supp. 2d 182, 77 U.S.P.Q. 2d (BNA) 1693, 2005 U.S. Dist. LEXIS 7923, 2005 WL 1027049
CourtDistrict Court, D. Massachusetts
DecidedApril 29, 2005
DocketCIV.A. 03-11323 PBS
StatusPublished

This text of 367 F. Supp. 2d 182 (Inverness Medical Switzerland GmbH v. Acon Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Inverness Medical Switzerland GmbH v. Acon Laboratories, Inc., 367 F. Supp. 2d 182, 77 U.S.P.Q. 2d (BNA) 1693, 2005 U.S. Dist. LEXIS 7923, 2005 WL 1027049 (D. Mass. 2005).

Opinion

MEMORANDUM AND ORDER

SARIS, District Judge.

I. INTRODUCTION

Defendant Aeon Laboratories, Inc. (“Aeon”) defends a patent infringement suit 1 by plaintiffs Inverness Medical Switzerland GmbH, Unipath Diagnostics, Inc., and Church & Dwight Co., Inc. (“Inverness”) by claiming, inter alia, that claims 7 and 19 of U.S. Patent No. 6,485,982 (“the ’982 patent”) are invalid for failure to meet the written description requirement under 35 U.S.C. § 112, ¶ 1. Aeon argues that because the ’982 patent specification, which is also the specification in the original patent application, only describes a test device contained in a casing, the patent does not satisfy the written description requirement as to the ’982 patent claims for a test device without a casing. Inverness .moves for partial summary judgment on Aeon’s written description theory. After hearing and review of the briefs, Inverness’s motion is ALLOWED.

II. BACKGROUND

The following facts are undisputed. In June 1988, Edmund Pitcher, Esq., on behalf of David Charlton and Neil Miller, filed U.S. Patent Application No. 07/211,-582 (“the ’582 application”) at the United States Patent and Trademark Office (PTO) on an immunoassay test device. That application eventually led, through a series of continuation applications, to three patents: U.S. Patent No. 5,714,389 (“the ’389 patent”) issued February 3,1998; U.S. Patent No. -5,989,921 (“the ’921 patent”) issued *184 November 23, 1999; and the patent at issue here, the ’982 patent, issued November 26, 2002.

The specification in the original ’582 application and the accompanying figures describe a test device enclosed in a type of housing or “casing.” The claims in the ’389 and ’921 patents, which share the ’582 patent specification, cover test devices enclosed in casings. Claims for a test device without a casing were first submitted to the PTO by Pitcher in May of 1997. The amendment that added these claims stated that the new claims were supported by the ’582 application specification. (Shiferman Decl., Ex. B at C00154-56.)

The ’982 patent, issued in 2002, claims a test device without a casing. The ’982 patent abstract states that the invention “includes an elongate outer casing which houses an interior permeable material .... ” Figures 1, 2 and 4A show the casing and the test strip, or the “sorbent material,” as two components with different reference numbers. The description of figures 1 and 2 states that an embodiment of the invention “comprises an outer molded casing ... filled with a permeable, sorbent material.” ’982 patent at col. 5, lines 33-35. As can be seen in the drawing below, figure 4A shows the test strip as a component separate from the casing (with casing at 10 and test strip at 12).

[[Image here]]

III. DISCUSSION

A. Summary Judgment Standard

“Summary judgment is appropriate when ‘the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to judgment as a matter of law.’ ” Barbour v. Dynamics Research Corp., 63 F.3d 32, 36 (1st Cir.1995) (quoting Fed. R.Civ.P. 56(c)). “To succeed [in a motion for summary judgment], the moving party must show that there is an absence of evidence to support the nonmoving party’s position.” Rogers v. Fair, 902 F.2d 140, 143 (1st Cir.1990); see also Celotex Corp. v. Catrett, 477 U.S. 317, 325, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986).

“Once the moving party has properly supported its motion for summary judgment, the burden shifts to the non-moving party, who ‘may not rest on mere allegations or denials of his pleading, but must set forth specific facts showing there is a genuine issue for trial.’ ” Barbour, 63 F.3d at 37 (quoting Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 256, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986)). “There must be ‘sufficient evidence favoring the nonmoving party for a jury to return a verdict for that party. If the evidence is merely colorable or is not significantly probative, summary judgment may be granted.’ ” Rogers, 902 F.2d at 143 (quoting Anderson, 477 U.S. at 249-50, 106 S.Ct. 2505) (citations in Anderson omitted). The Court must “view the facts in the light most favorable to the non-moving party, drawing all reasonable inferences in that *185 party’s favor.” Barbour, 63 F.3d at 36 (citation omitted).

B. Written Description Doctrine

Aeon argues that the ’982 patent fails the written description requirement of 35 U.S.C. § 112, ¶ 1, which provides:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.

“The purpose of the written description requirement is to prevent an applicant from later asserting that he invented that which he did not.” Amgen Inc. v. Hoechst Marion Roussel Inc., 314 F.3d 1313, 1330 (Fed.Cir.2003). The original patent specification must therefore “ ‘describe the claimed invention so that one skilled in the art can recognize what is claimed.’ ” Koito Mfg. Co., Ltd. v. Turn Key Tech, LLC, 381 F.3d 1142, 1154 (Fed.Cir.2004) (quoting Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956, 968 (Fed.Cir.2002)). “In evaluating whether a patentee has fulfilled this requirement, our standard is that the patent’s ‘disclosure must allow one skilled in the art’ to visualize or recognize the identity of the subject matter purportedly described.” Koito, 381 F.3d at 1154 (citations omitted).

The written description requirement comes into play where, as here, “a claim is' added by an applicant for a patent at some stage after the original filing date and the claim differs in scope from the original claims.” Donald S. Chisum, Chi-sum on Patents

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Barbour v. Dynamics Research Corp.
63 F.3d 32 (First Circuit, 1995)
Ralph Rogers v. Michael Fair
902 F.2d 140 (First Circuit, 1990)
Pin/nip, Inc. v. Platte Chemical Company
304 F.3d 1235 (Federal Circuit, 2002)
Inverness Medical Switzerland GMBH v. Acon Laboratories, Inc.
323 F. Supp. 2d 227 (D. Massachusetts, 2004)
United States v. Jason Moreno
809 F.3d 766 (Third Circuit, 2016)
Eiselstein v. Frank
52 F.3d 1035 (Federal Circuit, 1995)
Purdue Pharma L.P. v. Faulding Inc.
230 F.3d 1320 (Federal Circuit, 2000)
Enzo Biochem, Inc. v. Gen-Probe Inc.
42 F. App'x 439 (Federal Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
367 F. Supp. 2d 182, 77 U.S.P.Q. 2d (BNA) 1693, 2005 U.S. Dist. LEXIS 7923, 2005 WL 1027049, Counsel Stack Legal Research, https://law.counselstack.com/opinion/inverness-medical-switzerland-gmbh-v-acon-laboratories-inc-mad-2005.